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This review provides an overview of emerging techniques, namely, photodynamic diagnosis
(PDD), narrow band imaging (NBI), Raman spectroscopy, optical coherence tomography, virtual
cystoscopy, and endoscopic microscopy for its use in the diagnosis and surveillance of bladder
cancer. The technology, clinical evidence and future applications of these approaches are
discussed with particular emphasis on PDD and NBI. These approaches show promise to optimise
cystoscopy and transurethral resection of bladder tumours.
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1. INTRODUCTION
Bladder cancer is the ninth most common cancer in the world, affecting more than 356,600 people each
year. It has the highest incidence in Egypt followed by Europe and North America [1]. The majority of
diagnosed patients (75–85 percent) present with nonmuscle invasive bladder cancer (NMIBC), which is
characterised by a probability of recurrence at 1 and 5 years of 15–61 and 31–78 percent, respectively.
Moreover, progression of disease is seen in this group from <1–17% and <1–45% at 1 and 5 years,
respectively [2].
Flexible cystoscopy and voided urine cytology are currently the initial investigations of choice for
patients with symptoms suggestive of bladder cancer. The mainstay of treatment for NMIBC is complete
transurethral resection (TUR), ultimately preventing disease recurrence and progression. It is postulated that
bladder cancer recurrence occurs via four mechanisms: incomplete resection, tumour cell reimplantation,
growth of microscopic tumours, and new tumour formation [3]. First tumour recurrence appears different
to subsequent recurrences; incomplete resection and tumour cell reimplantation may dominate at this time-
point and are therefore inﬂuenced by clinicians before and immediately after resection [4]. Only later does
genuine new tumour formation appear to increase in importance where chemopreventive agents may have
its role in reducing recurrence.
Nonmuscle invasive urothelial transitional cell cancer (UC) of the bladder is one of the most
expensive cancers to manage on a per patient basis, because of its high prevalence, high recurrence rate,
and the need for long-term cystoscopic surveillance. The total cost of treatment and 5-year followup of
patients with NMIBC diagnosed during 2001-2002 in the United Kingdom was over £35 million [5]. Direct
cost of managing bladder cancer in the USA is estimated to range from $96,000–$187,000 per patient from
the diagnosis to death [6]. Furthermore, health technology assessments have demonstrated the addition
of photodynamic diagnosis (PDD) and urinary biomarkers adds to the cost which can have implications
towards service provision [7, 8].
Developments in optical diagnostics might reduce the limitations of current methods of detection
and surveillance in several ways. These emerging techniques aim at cystoscopy for better visualisation of
bladder tumours or predict histopathologic diagnosis in realtime. We aim to review these relatively new
technologies for their ability to improve the diagnostic yield.
2. METHODS
A PubMed literature search was performed for this nonsystematic review, and papers on photodynamic
diagnosis (PDD), narrow-band imaging (NBI), Raman spectroscopy (RS), optical coherence tomography
(OCT),virtualcystoscopy(VC),andendoscopic-microscope(EM)regardingbladdercancerwerereviewed.
3. PHOTODYNAMIC DIAGNOSIS (PDD)
PDD is a technique that has been proposed to enhance tumour detection and resection. The principle of PDD
is based on the interaction between a photosensitising agent with a high uptake by tumour cells and light
with an appropriate wavelength, which is absorbed by the agent and reemitted with a different wavelength
[9].
Several commercially available agents have been used to induce exogenous ﬂuorescence, but
presently hypericin, 5 aminolaevulinic acid (5-ALA), and its ester hexaminolevulinate (HAL) are applied
most often. Optimal dose and instillation time have not yet been determined. One retrospective trial
compared the performance of PDD with HAL and with 5-ALA [10]. No signiﬁcant differences were
found between 5-ALA and HAL in this study. A randomised comparison of both substances has never
been performed.
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Several clinical trials have shown that detection of bladder cancer with PDD is superior to white
lightcystoscopy(WLC).Inasystematicreviewandmeta-analysis,twenty-sevenstudies(2,949participants)
were assessed for test performance [11]. PDD had higher sensitivity than WLC (92%, 95 percent conﬁdence
interval [CI], 80–100% versus 71%, 95 percent CI, 49–93%) but lower speciﬁcity (57%, 95 percent CI, 36–
79% versus 72%, 95 percent CI, 47–96%).
In order to predict short- and long-term risks of recurrence and progression, the EORTC-GU group
has developed a scoring system and risk table based on number of tumours, tumour size, prior recurrence
rate, T-category, presence of concurrent CIS, and tumour grade into low, intermediate, and high risk groups
[2]. For detecting higher-risk tumours, median range sensitivity of PDD (89%, 95 percent CI, 6–100%)
was higher than WLC (56%, 95 percent CI, 0–100%) whereas for lower-risk tumours, it was broadly
similar (92%, 95 percent CI, 20–95%) versus 95%, (95 percent CI, 8–100%). The higher sensitivity of
PDD was also reﬂected in the detection of CIS alone. Four randomised clinical trials (RCTs) involving
709 participants using 5 aminolaevulinic acid (5-ALA) as the photosensitising agent reported clinical
effectiveness. Using PDD at transurethral resection of bladder tumour (TURBT) resulted in fewer residual
tumours at check cystoscopy (relative risk [RR], 0.37, 95 percent CI, 0.20–0.69) and longer recurrence-free
survival (RR, 1.37, 95 percent CI, 1.18–1.59), compared with WLC. However, the advantages of PDD at
TURBT in reducing recurrence and progression in the longer term were less clear [8].
A recent study examined the frequency of HAL-ﬂuorescence-detected residual tumours immediately
after standard WL TURBT and the efﬁcacy of immediate removal of residual tumour tissue or overlooked
tumours on tumour recurrence. Patients were ﬁrst inspected and resected with white light before undergoing
inspection and further resection with blue light HAL ﬂuorescence cystoscopy. It was therefore possible
not only to identify previously overlooked lesions, but also to identify areas of residual tumour where
the resection under white light had not been complete. Fluorescence-guided cystoscopy after complete WL
TURBTidentiﬁedresidualtumourtissuein44of90patients(49%).Therecurrencerateinpatientsfollowed
for 12 months was 47.3% after WL TURB and 30.5% after HAL TURBT (P = 0.05) [12]. This study also
demonstrates the potential of using PDD TURB as a teaching tool to offer clear visualisation of tumours
and their margins, thereby facilitating improved TURBT.
The European expert panel recommended HAL-guided PDD use on all patients with initial suspicion
of bladder cancer [13]. However, a recent cost analysis demonstrated that PDD added a high cost to beneﬁt
ratio if applied to all patients in detection and surveillance of bladder cancer [8]. Nonetheless, PDD may
be cost effective in selected group with high-risk disease for surveillance. This remains to be determined.
Furthermore, PDD may have its role in patients with positive urine cytology but negative WLC.
4. NARROW-BAND IMAGING (NBI)
NBI is an optical image enhancement technique designed for endoscopy to enhance the contrast between
mucosal surfaces and microvascular structures without the use of dyes. This narrow band of light is strongly
absorbed by haemoglobin and penetrates only the surface of tissue, increasing the visibility of capillaries
and other delicate tissue surface structures [14].
Level I evidence (meta-analysis) of NBI use is lacking in bladder cancer [15] but does exist in the
ﬁeld of gastro-enterology for detection of colonic adenoma [16], high-grade dysplasia and metaplasia in
Barrett’s oesophagus [17].
There are few studies published assessing the value of NBI in bladder cancer. All found a subjective
improvement of visualisation of the tumours. Bryan et al. performed ﬂexible WLC and subsequent NBI
cystoscopy in 29 patients with recurrent NMIBC. NBI cystoscopy revealed 15 additional tumours in 12
patients [14]. However, the additional tumours were not conﬁrmed with histology since all tumours were
treated with diathermy ablation. In a further study involving 23 patients by the same group demonstrated
that even “new users” to NBI technology demonstrate a signiﬁcantly improved detection rate of bladder
cancer using NBI versus WLC alone [18]. Herr et al. performed WLC with subsequent NBI cystoscopy in
427consecutivepatientswithahistoryofNMIBC.Recurrencewasfoundin103patients.In56%ofpatients
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w i t har e c u r r e n c e( n = 58), additional tumours were detected by NBI, and in 12% of patients (n = 13), the
bladder tumours were detected only by NBI.
A prospective controlled study of NBI was conducted in 104 consecutive patients with deﬁnite or
suspected bladder cancer by Tatsugami and colleagues [19]. They reported a sensitivity and speciﬁcity
for the detection of bladder tumours using NBI in all patients versus those with CIS of 92.7% and 70.9
versus 89.7% and 74.5%, respectively. The sensitivity and speciﬁcity for the detection of bladder tumours
using NBI in patients with positive versus negative urine cytology were 85.4% versus 98.4% and 75.7%
versus 66.3%, respectively. For WLC and NBI cystoscopy, the overall sensitivity was 87% and 100% and
the overall speciﬁcity 85% and 82%, respectively [20]. A limitation of this study is the possible observer
bias, since WLC and NBI were performed subsequently by the same urologist. In order to address observer
bias a recent randomized trial conﬁrmed that a “second look” did not compromise the superiority of NBI
over standard WLI ﬂexible cystoscopy for detecting primary NMIBC including CIS lesions [38]. Whether
the speciﬁcity of NBI will be negatively inﬂuenced by previous intravesical instillations, inﬂammation, or
scarring, like PDD, is yet unknown.
Reassuringly, NBI cystoscopy does not appear to have a “learning curve” for its adaptation in
surveillance for patients with bladder cancer [21].
5. RAMAN SPECTROSCOPY (RS)
RS enables measurement of molecular components of tissue in a qualitative and quantitative way. The
principle of this optical technique is based on the Raman effect or inelastic scattering. Raman molecular
imaging (RMI) is an optical technology that combines the molecular chemical analysis of Raman
spectroscopy with high-deﬁnition digital microscopic visualisation [9]. This approach permits visualisation
of the physical architecture and molecular environment of cells in the urine. The Raman spectrum of a cell
is a complex product of its chemical bonds.
Several groups have determined the diagnostic accuracy of RS by comparing ex vivo Raman
measurementsofbladdersampleswithhistology.Generally,thetimeneededtoobtainthespectraisbetween
1 and 5 seconds [22]. Shapiro and colleagues investigated urine samples from 340 patients, including 116
patients without UC, 92 patients with low-grade tumors, and 132 patients with high-grade tumours. The
Raman spectra from UC tissue demonstrate a distinct peak at a 1584cm−1 wave shift not present in benign
tissues. The height of this peak correlated with the tumour’s grade. The signal obtained from epithelial cells
correctly diagnosed bladder cancer with sensitivity of 92% (100% of the high-grade tumors), speciﬁcity
of 91%, a positive predictive value of 94%, and a negative predictive value of 88%. The signal correctly
assigned a tumour’s grade in 73.9% of the low-grade tumors and 98.5% of the high-grade tumours [23].
RMI for diagnosis of bladder cancer is limited by the need for specialised equipment and training
of laboratory personnel. For in vivo measurements, small, ﬂexible ﬁbre-optic probes compatible with the
working channel of a rigid or ﬂexible cystoscope have been developed [22], but the application has been
hamperedbymanytechnicalissues[9].Therefore,furtherstudiesdemonstratinghumaninvivoapplicability
of RS on bladder tissue are still awaited.
6. OPTICAL COHERENCE TOMOGRAPHY (OCT)
OCT produces high-resolution, cross-sectional images of tissue. The principle of this optical technique is
analogous to B-mode ultrasonography except that light is being used instead of sound [24].
Karl et al. enrolled 52 patients who underwent transurethral bladder biopsy or TUR-BT for
surveillance or due to initial suspicion of UC of the bladder. In total, 166 lesions were suspicious
for malignancy according to standard white light cystoscopy. All suspicious lesions were scanned and
interpreted during perioperative cystoscopy using OCT, and then subsequently biopsied by cold cup or
TUR for pathological conﬁrmation. There were no false-negative lesions detected by OCT. Sensitivity of
OCT for detecting the presence of a malignant lesion was 100% and sensitivity for detection of tumor
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growth beyond the lamina propria was 100% as well. Speciﬁcity of OCT for presence of malignancy was
65%, due to the fact that a number of lesions were interpreted as false positive by OCT [25].
As a minimally invasive technique, OCT demonstrates high sensitivity for detection of malignant
lesions as well as estimation of whether a tumour has invaded beyond the lamina propria [24, 26, 27].
However, speciﬁcity of OCT within the bladder is low, possibly due to a learning curve and/or the
relativelylowspatialresolutionandvisualisationdepthoftheOCTtechnology.Furtherstudiesandtechnical
development are needed to establish an adequate surrogate for optical biopsy.
Advantages of OCT can be found in the noninvasive, real-time, and high-resolution images that are
comparable with histopathology and provide information about depth of tumour growth. However, reliable
measurements of muscle-invasive tumours may be hampered due to insufﬁcient imaging depth. OCT is less
suitable for screening the entire bladder, thus in the absence of visually suspect lesions, it has to be used in
combination with other methods (e.g., NBI or PDD) to direct to the region of interest.
7. VIRTUAL CYSTOSCOPY (VC)
With the progressive development in diagnostic imaging and medical computer software technologies, it
is possible to generate virtual reality images to aid the clinician to inspect the interior of the bladder in
real time. VC can be applied to any imaging modality be it computerised tomography (CTVC), magnetic
resonance imaging (MRVC), or ultrasound (USVC).
A metaanalysis comparing virtual cystoscopy and ultrasonography (US) was reported by Qu and
colleagues [28]. A total of 26 studies that included 3084 patients who fulﬁlled all of the inclusion criteria
were considered for inclusion in the analysis. The pooled sensitivity for bladder cancer detection using CT
virtual cystoscopy (CTVC), MR virtual cystoscopy (MRVC), and US was 0.939 (95% CI, 0.919–0.956),
0.908 (95% CI, 0.827–0.959), and 0.779 (95% CI, 0.744–0.812), respectively. The pooled speciﬁcity for
bladder cancer detection using CTVC, MRVC, and US was 0.981 (95% CI, 0.973–0.988), 0.948 (95%
CI, 0.884–0.983), and 0.962 (95% CI, 0.953–0.969), respectively. The pooled diagnostic odd ratio (DOR)
estimate for CTVC (604.22) was signiﬁcantly higher than for MRVC (144.35, P < 0.001) and US (72.472,
P <0.001). Results showed that both CTVC and MRVC are better imaging methods for diagnosing bladder
cancer than US. CTVC has higher diagnostic value (sensitivity, speciﬁcity, and DOR) for the detection of
bladder cancer than either MRCT or US.
CT virtual cystoscopy is a noninvasive technique that can be used successfully for detection of
bladdertumours>5mminselectedcasesduringdailyroutineabdominopelvicwork.UCs>5mmrepresent
the majority of newly diagnosed bladder tumours: in the Bladder Cancer Prognosis Programme [29], only
6.7% of 1075 conﬁrmed UCs were 5mm or less in size (unpublished data). In some series, lesions as small
as 2×3mm have been detected [30], but this technique is still unable to detect ﬂat lesions that may represent
CIS [31]. Moreover, the effects of ionising radiation are a signiﬁcant obstacle to such modalities being used
routinely for diagnosis and surveillance of bladder cancer.
8. ENDOSCOPIC MICROSCOPE (EM)
EM is a novel, low-cost, high-resolution endoscopic microscope for obtaining ﬂuorescent images of the
cellular morphology of the epithelium. Its experimental use as a noninvasive point imaging system offers
a method for obtaining real-time histologic information during endoscopy [32]. Whilst it is feasible to
obtain high-resolution histopathologic information using the endoscopic microscope device, the difﬁculties
of holding a ﬁne (1.4–2.6mm in diameter) instrument still to capture the image within the bladder makes
obtaining interpretable images challenging. Future improvement and integration with wide ﬁeld endoscopic
techniques will aid in improving the sensitivity of detection of dysplasia and early cancer development in
epithelial cancers like the oesophagus or bladder.
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TABLE 1: Overview of NBI and PDD techniques.
NBI PDD
Optical principle Absorption Fluorescence
Costs stack Equivalent Equivalent
Costs scopes
Can be used on compatible
“scopes”
New rigid “scopes” with blue light ﬁlter
are required
Costs staff Nil Extra
Costs consumables Nil Extra
Convenience Very convenient Inconvenient
Extra invasiveness for patient None
Extra catheterisation for preoperative
instillation of photosensitising agent
Sensitivity (%) for visualisation of
bladder tumours
93–100 82–97
Speciﬁcity (%) for visualisation of
bladder tumours
68–82 41.4–98.5
On Initial suspicion of bladder cancer
diagnosis
Good in an outpatient setting at
initial cystoscopy
Good in an inpatient setting at time of
TURBT
On CIS diagnosis Accuracy of 83% [38] Good
In patients with positive urine
cytology but negative WLC
Not known Recommended
For assessment at time of tumour




Good in outpatient setting for
ablation of tumours by diathermy
or laser, especially for
recurrences during surveillance
Good in an inpatient setting in
conjunction with TURBT
Haematuria clinic Considerable potential
Impractical due to patient numbers and
not all patients presenting to haematuria
clinic have UC
For surveillance
Good. Effect of previous BCG,
inﬂammation or scarring is yet
unknown
No data available. Speciﬁcity is reduced
in patients who have had previous BCG,
inﬂammation, or scars and hence limits
the use
Extra applications
Upper urinary tract, upper and
lower GI, and so forth
Nil
As a teaching tool Good Good
9. CONCLUSION
As described earlier, the 4 mechanisms of bladder UC recurrence are incomplete resection, tumour cell
reimplantation, growth of microscopic tumours, and new tumour formation [3]. Incomplete resection and
tumour cell reimplantation at the site of the primary tumour are proposed to be the most important causes
of early UC recurrence, as well as the growth of very small volume or microscopic tumours that were
present but overlooked at the time of the primary resection [3]. Improving optical technologies is one way
to overcome these WLC shortfalls. In this regard, PDD and NBI are the most mature technologies and
are currently in widespread clinical use. An overview of these two most studied approaches is outlined in
Table 1. The other modalities described above may also facilitate the detection of very small volume or
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microscopic lesions, but their future is more likely to lie with “real-time” tumour staging. An instrument
that combines some or all of these technologies may be the ultimate goal for the urologist, but this is some
way off yet.
Another strategy to improve our optical diagnosis of bladder UCs is by improving cystoscopy skills.
Cystoscopy may not be taught as well as it should. This may be due to poor training and the assumption
that junior urologists do not need formal training in performing cystoscopy and are not assessed in this.
Moreover, delegation of the large volume of followup cystoscopy is usually to junior and inexperienced
staff. Also, failure to use the best endoscopy equipment and not employing the 70-degree telescope are
possible reasons for poor-quality TURBTs, even amongst experienced urologists. The absence of detrusor
muscle in the ﬁrst apparently complete, white light TURBT by less-experienced surgeons appears to be
independently associated with an increased risk of recurrence [33]. TURBT should be performed in a timely
fashionandunderstandardconditions.Theseincludeuseofproperanaesthesiawithacontinuous-ﬂowvideo
resectoscope. The entire bladder must be visualised and all abnormal areas must be resected, with separate
biopsies from each tumour’s base, speciﬁcally to avoid understaging muscle-invasive disease. Restaging
TURBTisrecommendedforallhigh-gradetumours, particularlyifthe muscleisnotpresentinthespecimen
[34]. The main evidence for this is supported by Herr showing the large number of tumours missed and the
high recurrence rate [35]. This is thought due to inadequate training, technique, or both. Users of PDD/NBI
have often reported that “these techniques make one a better cystoscopist” by focusing the operator in taking
longer and looking more thoroughly. From personal experience, when we ﬁrst started using NBI ﬂexible
cystoscopy in 2005, we were surprised at just how many UCs we were missing with WLC, and quickly
learnt to recognise some of the very subtle mucosal changes that were visible with WLC that accompanied
the lesions that we had only initially seen with NBI. Other authors describe how they now routinely resect or
diathermy a margin around the base of the primary UC as a result of what they have seen when performing
TURs with PDD [36].
Data from this review indicate at evidence levels 1 and 2 (metaanalysis of randomised controlled
and good-quality prospective cohort studies) that PDD detects signiﬁcantly more tumour-positive patients
than white-light cystoscopy alone. This may come at the price of reduced speciﬁcity. The detection beneﬁt
is higher in selected patients with carcinoma in situ (evidence level 2). PDD reduces residual tumour rates
and increases tumour-free survival signiﬁcantly (evidence level 1). Measures to make it more cost effective
include using PDD in a more selective setting such as those with high-risk disease (EORTC-GU group
tables) at ﬁrst diagnosis or in patients with positive urine cytology but negative WLC.
Although a clear beneﬁt for PDD has been found for the detection of CIS, the value of this
technique with respect to CIS recurrences and progression remains unclear. The beneﬁt of PDD with
respect to progression must also be demonstrated in papillary disease especially over the course of long-
term surveillance. Presently no data exists on which to base a ﬁrm recommendation for the use of PDD
for surveillance. Future studies will have to show if the intervals to followup cystoscopy can be altered
when PDD is used and if PDD changes adjuvant treatment, for instance, due to the safe exclusion of CIS.
Furthermore, the necessity of re-TUR after PDD must be evaluated.
With both NBI and PDD there remain the issues of whether the procedures are carried out more
diligently when the new modality is used [36], or whether the improvements are due to a “second look”
cystoscopy [37]. However, a recent study has concluded that “a second look does not compromise the
superiority of NBI over standard WLC ﬂexible cystoscopy for detecting primary NMIBC including CIS
[38].”
Other techniques discussed, namely, RS, OCT, VC, and EM show promising preliminary results, but
more research is needed before any of the techniques can be instituted in the diagnosis and surveillance of
bladder cancer. There is clearly a need for larger, multicentre RCT in these emerging approaches, especially
NBI and PDD for diagnosis and surveillance of bladder cancer. A CROES trial is currently recruiting in the
NBI TUR setting, and other trials using NBI and PDD for bladder cancer surveillance are in planning.
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